-
Onyx Makes Headway with Carfilzomib - Analyst Blog
Tuesday, February 1, 2011 - 11:00am | 624Onyx Pharmaceuticals Inc. (ONXX) recently said that the US Food and Drug Administration (FDA) granted a fast track designation to carfilzomib, a next generation proteasome inhibitor, under evaluation for the treatment of patients with relapsed and refractory multiple myeloma. Earlier, in...
-
Manufacturing, Earnings & Global Events - Ahead of Wall Street
Tuesday, February 1, 2011 - 10:01am | 503Hey! Has anyone else noticed no one is talking about hitting Dow 12,000 anymore? That darned Egypt -- sure, they may have invented Western society, but what have they done for us lately? ;) Seriously, protesters in Egypt have staged their largest demonstration against President Mubarak to date,...
-
Sanofi, Genzyme May Reach Deal in One Week (SNY, GENZ)
Tuesday, February 1, 2011 - 9:54am | 232Sanofi-Aventis (NYSE: SNY) and Genzyme (NASDAQ: GENZ) have agreed to a deal in principle, and the deal may actually be finalized in a week, according to the Wall Street Journal. Genzyme has previously rejected the $69 per share offer for the company, and wanted closer to $80 per share, but...
-
Benzinga's Top Downgrades (JBLU, JNJ, DISCA, AMB)
Tuesday, February 1, 2011 - 9:40am | 135JetBlue Airways Corporation (NASDAQ: JBLU) was downgraded by Argus from "buy" to "hold." JBLU's shares closed at $6.00 yesterday. JetBlue Airways' PEG ratio is 2.13. Johnson & Johnson (NYSE: JNJ) was downgraded by First Global from "outperform" to "market perform." JNJ's stock closed at $59.77...
-
Manufacturing, Earnings & Global Events - Ahead of Wall Street
Tuesday, February 1, 2011 - 9:33am | 503Hey! Has anyone else noticed no one is talking about hitting Dow 12,000 anymore? That darned Egypt -- sure, they may have invented Western society, but what have they done for us lately? ;) Seriously, protesters in Egypt have staged their largest demonstration against President Mubarak to date,...
-
Benzinga's Top Pre-Market NASDAQ Losers (OREX, VVUS, CCME, DEPO)
Tuesday, February 1, 2011 - 9:30am | 119Orexigen Therapeutics Inc (NASDAQ: OREX) dipped 73.82% to $2.38 in the pre-market session. The Food and Drug Administration (FDA) declined to approve the OREX's diet drug Contrave. VIVUS Inc (NASDAQ: VVUS) fell 7.82% to $8.25 in the pre-market session. VVUS' PEG ratio is -0.17. China MediaExpress...
-
Trading Orexigen Therapeutics Terrible Results (OREX, ARNA, VVUS)
Tuesday, February 1, 2011 - 9:26am | 171Orexigen Therapeutics, Inc. (NASDAQ: OREX) shares are getting hammered in pre-market trading, down over 70% after the FDA said it wants Orexigen to conduct additional tests for Contrave, its weight loss drug. The concerns are over heart safety issues. The FDA said it may eventually approve the...
-
Pfizer Reports Q4 EPS of $.47 vs. $.46
Tuesday, February 1, 2011 - 9:01am | 44Pfizer Inc. (NYSE: PFE) today reported financial results for fourth-quarter. Fourth-Quarter 2010 Revenues of $17.6 Billion; Full-Year 2010 Revenues of $67.8 Billion Fourth-Quarter 2010 Adjusted Diluted EPS of $0.47, Reported Diluted EPS of $0.36; Full-Year 2010 Adjusted Diluted EPS of $2.23,...
-
Deutsche Bank Maintains Buy Rating, $20 PT On MAPP
Tuesday, February 1, 2011 - 8:57am | 114Deutsche Bank is maintaining its PT and rating on MAP Pharmaceuticals, Inc. (NASDAQ: MAPP). “Based upon a significant unmet need among migraine sufferers and positive clinical results to date, we continue to believe that Levadex is a compelling opportunity that could potentially generate peak WW...
-
Perrigo Reports Q2 EPS of $1.05 vs. $.95
Tuesday, February 1, 2011 - 8:56am | 67Perrigo Company (Nasdaq: PRGO) today announced results for its second quarter and six months ended December 25, 2010. Fiscal second quarter revenue from continuing operations increased $135 million, or 23%, to $718 million Fiscal second quarter GAAP income from continuing operations increased 43%...
-
Jefferies Maintains Hold on Allergan (AGN)
Tuesday, February 1, 2011 - 8:23am | 111Jefferies is out with its report today on Allergan (NYSE: AGN), maintaining Hold and a $74 PT. In its note to clients, Jefferies writes, "AGN has in-licensed Levadex, a Phase III therapy for acute migraine. This builds on AGN's CNS/neurology franchise, especially now that Botox for chronic...
-
US Stock Futures Up As Investors Await Economic Data, Earnings Reports; Pfizer Results In Focus
Tuesday, February 1, 2011 - 7:46am | 386US stock futures are higher this morning, as investors are awaiting earnings from Pfizer Inc (NYSE: PFE) and other major companies. Futures on the Dow Jones Industrial Average advanced 43 points to 11,883.00 and S&P 500 futures gained 6.60 points to 1,289.00. Nasdaq 100 futures climbed 14.50...
-
Earnings Scheduled For February 1 (UPS, PFE, BIIB, ADM, COV, CE, MHP, LXK, BRCM, AFL, ERTS, BSX, WU)
Tuesday, February 1, 2011 - 4:20am | 337United Parcel Service Inc (NYSE: UPS) is expected to report its Q4 earnings at $1.05 per share on revenue of $13.41 billion. Pfizer (NYSE: PFE) is projected to report its Q4 EPS at $0.46 on revenue of $16.99 billion. Biogen Idec (NASDAQ: BIIB) is estimated to report its Q4 earnings at $1.23 per...
-
Stocks To Watch For February 1 (PFE, NVLS, UPS, APC, ERTS)
Tuesday, February 1, 2011 - 4:14am | 265Some of the stocks that may grab investor focus today are: Wall Street expects Pfizer (NYSE: PFE) to report its Q4 EPS at $0.46 on revenue of $16.99 billion. PFE shares fell 0.22% to $18.18 in after-hours trading. Novellus Systems Inc (NASDAQ: NVLS) reported its Q4 profit at $81.5 million, or $0.89...
-
Perrigo Company (PRGO) - Bull of the Day
Tuesday, February 1, 2011 - 3:01am | 166Perrigo Company (PRGO) reported first quarter fiscal 2011 EPS of $0.87, well above the Zacks Consensus Estimate of $0.77. We believe that Perrigo's strong position in the brand OTC pharmaceutical market and growing generics and API businesses will help it deliver solid top- and bottom-line growth...